Caladrius Announces Publication of Two-Year Results From Phase 1 Trial of Type 1 Diabetes Product Candidate in Science ...
BASKING RIDGE, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (“Caladrius” or the “Company”) (NASDAQ:CLBS), a cell therapy company combining an industry-leading external development and manufacturing provider with a development …